Sanofi will sell Zentiva, its European generics business, to private equity investor Advent International.
Sanofi and Advent International, a private equity investor, announced on June 28, 2018 that they finished negotiations for Advent to acquire Sanofi’s European generics business, Zentiva, in a share purchase agreement worth EUR 1.9 billion (US$2.2 billion).
The transaction remains subject to approval by regulatory authorities. The companies announced that they had entered into exclusive talks in April 2018. According to Sanofi, the signing of this agreement marks a critical step for the deal, which is expected to close during the fourth quarter of 2018.
Zentiva, headquartered in Prague, Czech Republic, provides generic drugs covering a range of therapeutic areas and reaches over 40 million patients in 25 European countries. The business has manufacturing facilities in Prague and Bucharest, Romania, that produce and distribute more than 350 million packs each year.
Source: Sanofi
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.